UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE TO

Tender Offer Statement under Section 14(d)(1) or 13(e)(1)
of the Securities Exchange Act of 1934

G1 THERAPEUTICS, INC.

(Name of Subject Company (Issuer))

GENESIS MERGER SUB, INC.

(Offeror)

A wholly-owned subsidiary of

PHARMACOSMOS A/S

(Parent of Offeror)
(Names of Filing Persons (identifying status as offeror, issuer or other person))

Common Stock, $0.001 Par Value Per Share
(Title of Class of Securities)

3621LG109
(Cusip Number of Class of Securities)

Milena Jordanova Olsen
General Counsel
Pharmacosmos A/S
Roervangsvej 30
DK-4300 Holbaek, Denmark
Telephone: +45 5948 5959
(Name, address, and telephone numbers of person authorized to receive notices and communications on behalf of filing persons)

Copies to:

Lowell Dashefsky, Esq.
Michael Penney, Esq.
Arnold & Porter Kaye Scholer LLP
250 West 55th Street
New York, New York 10019
(212) 836-8000

Transaction Value*	**Amount of Filing Fee***
N/A	N/A

*Pursuant to General Instruction D to Schedule TO, a filing fee is not required in connection with this filing because it relates solely to preliminary communications made before the commencement of a tender offer.

☐ Check the box if any part of the fee is offset as provided by Rule 0-11(a)(2) and identify the filing with which the offsetting fee was previously paid. Identify the previous filing by registration statement number, or the form or schedule and the date of its filing.

Amount Previously Paid: N/A
Form or Registration No.: N/A
Filing Party: N/A
Date Filed: N/A

☒ Check the box if the filing relates solely to preliminary communications made before the commencement of a tender offer.

Check the appropriate boxes below to designate any transactions to which the statement relates:

☒ Third-party tender offer subject to Rule 14d-1.
☐ Issuer tender offer subject to Rule 13e-4.
☐ Going-private transaction subject to Rule 13e-3.
☐ Amendment to Schedule 13D under Rule 13d-2.

Check the following box if the filing is a final amendment reporting the results of the tender offer: ☐

If applicable, check the appropriate box(es) below to designate the appropriate rule provision(s) relied upon:

☐ Rule 13e-4(i) (Cross-Border Issuer Tender Offer)
☐ Rule 14d-1(d) (Cross-Border Third-Party Tender Offer)

This filing relates solely to preliminary communications made before the commencement of a planned tender offer by Genesis Merger Sub, Inc., a Delaware corporation ("Purchaser"), and an indirect wholly owned subsidiary of Pharmacosmos A/S, a Danish *aktieselskab* ("Parent"), for all of the outstanding shares of common stock, par value $0.0001 per share ("Shares"), of G1 Therapeutics, Inc., a Delaware corporation ("G1"), at a price of $7.15 per Share, net to the seller in cash, without interest and less any applicable withholding taxes, pursuant to an Agreement and Plan of Merger, dated as of August 6, 2024, by and among Parent, Purchaser and G1.

Notice to Investors

The tender offer (the "Offer") for the outstanding common stock of G1 referred to in this filing and related exhibit has not yet commenced. The description contained in this filing and related exhibit is neither an offer to purchase nor a solicitation of an offer to sell any securities, nor is it a substitute for the tender offer materials that Parent will file with the U.S. Securities and Exchange Commission (the "SEC"). The solicitation and offer to buy the common stock of G1 will only be made pursuant to an offer to purchase and related tender offer materials. At the time the Offer is commenced, Parent will file a tender offer statement on Schedule TO and, thereafter, G1 will file a solicitation/recommendation statement on Schedule 14D-9 with the SEC with respect to the Offer. THE TENDER OFFER MATERIALS (INCLUDING AN OFFER TO PURCHASE, A RELATED LETTER OF TRANSMITTAL AND CERTAIN OTHER OFFER DOCUMENTS) AND THE SOLICITATION/RECOMMENDATION STATEMENT ON SCHEDULE 14D-9 WILL CONTAIN IMPORTANT INFORMATION. ANY HOLDERS OF SHARES ARE URGED TO READ THESE DOCUMENTS CAREFULLY WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION THAT HOLDERS SHOULD CONSIDER BEFORE MAKING ANY DECISION REGARDING TENDERING THEIR SHARES. The offer to purchase, the related letter of transmittal and the solicitation/recommendation statement will be made available for free at the SEC's website at www.sec.gov. Free copies of the offer to purchase, the related letter of transmittal and certain other offering documents will be made available by Parent and when available may be obtained by directing a request to the Information Agent for the tender offer which will be named in the Schedule TO. Copies of the documents filed with the SEC by G1 will be available by accessing https://investor.g1therapeutics.com.

In addition to the offer to purchase, the related letter of transmittal and certain other tender offer documents filed by Parent, as well as the solicitation/recommendation statement filed by G1, G1 will also file annual, quarterly and current reports with the SEC. You may read and copy any reports or other information filed by Parent or G1 at the SEC public reference room at 100 F Street, N.E., Washington, D.C. 20549. Please call the SEC at 1-800-SEC-0330 for further information on the public reference room. G1's filings with the SEC are also available to the public from commercial document-retrieval services and at the website maintained by the SEC at http://www.sec.gov.

EXHIBIT INDEX

Exhibit No.	Description
99.1	Presentation by Pharmacosmos A/S to G1 Therapeutics, Inc. Employees on August 14, 2024.
99.2	Pharmacosmos A/S FAQ for G1 Employees first used on August 14, 2024.

G1 Townhall Meeting – August 2024

Introduction to Pharmacosmos

PHAR

TOBIAS S. CHRISTENSEN

President & CEO
MSc Eng

CLAES CHRISTIAN STRØM

Executive Vice President, CCO
MD, PhD, BBA

JOSH FRANKLIN

President, Pharmacosmos Therap

PHAR

Pharmacosmos Introduction

Our focus, ambition & solutions

PHAR


• Pharmacosmos has established a state-of-the-art production facility
• Factory designed and built specifica Pharmacosmos engineers
• The secret is in the carbohydrates a complexing technology
• Capacity to supply the whole world
• Entirely water-based – no organic s
PHAR

Sustainability Initiatives

- We do not use any organic solvents in our production.
- We have reduced our water consumption by developing an integrated water system utilising excess purified water into our cooling and heating processes
- The main ingredient in our production (sugar) is sourced and produced locally, and parts of our production waste are reused in animal feed and for the production of biogas
- 50% of the power consumed at our manufacturing site is sourced from wind and solar energy
- All of our non-biodegradable waste is sorted before being shipped for recycling or incineration for energy production


Pharmacosmos
A family-owned company
PHAR


1965
Established by Dr. H. Christensen. Initial focus on production of dextrans
1983
First FDA approval of iron dextran bulk solution for veterinary use
1992
FDA approved for supplying human IV iron API for use in the USA
2001
Approval of CosmoFer® in the EU
2003
Inaugurated state-of-the-art facility
2009
Approval of Monofer® in the EU
2014
Inaugurated carbohydrate derivatives synthesis facility
2019
Established US subsidiary for sales of human medicines
2020
Approval and launch of Monoferric® in the US
Established Chinese subsidiary
2021
Initiated commercialization of IV iron products in China
PHAR

Executive Management

TOBIAS S. CHRISTENSEN

President & CEO
MSc Eng

CLAES CHRISTIAN STRØM

Executive Vice President, CCO
MD, PhD, BBA

HENRIK F

Executive
MSc in B
and Audit

LARS LYKKE THOMSEN

Executive Vice President, CMO
MD, PhD, DMSc

MILENA JORDANOVA OLSEN

Executive Vice President,
General Counsel
Attorney at Law

INGEBOR

Vice Pres
Quality &
Cand. Ph

DITTE LINDBOE

Executive Vice President, HR
Cand. Merc. HRM

THOMAS BIRGER RIISAGER

Executive Vice President
Corporate Development &
Strategy

PHAR

Board Members

JACOB TOLSTRUP

Chairman of the Board of Directors

MARTIN HOLST LANGE

Member of the Board

LARS GREEN

Member of the Board



MILENA JOR

Member of the

LARS CHRISTENSEN

Deputy Chairman of the Board

PHAR

Global presence



Pharmacosmos present with affiliates

Pharmacosmos sales (Through partners)

600

worldwide

Note: FTEs including sales and other functions within the sales organisation, including vacant positions

Our Values

- People driven
- Committed to Quality
- Innovating for better lives

PHAR

People driven

We are a family-held company built on passionate, knowledgeable people. We value integrity, open-mindedness and respect and are guided by these values in all our endeavours. We respect each individual who becomes a part of our journey, from our employees and partners to our end-users. And we recognise that the strength in all our collaborations is trust.

- Committed to Quality
- Innovating for better lives



PHAR

Committed to quality

Quality is our source of inspiration. Quality drives our results. It represents our aspiration for excellence and our focus on driving continual improvements.

For our partners and end-users, quality must always be tangible in our products, processes and people.

This way, quality is the promise we keep every day.

- People driven
- Innovating for better lives

PHAR

Innovating for better lives

Innovation is essential in our quest to improve the lives of humans and animals. We seek to address unmet needs through our expertise in iron and carbohydrate-based pharmaceuticals. We believe in a holistic and collaborative approach to research and innovation, so we work together with the scientific and medical communities to set new standards.

- People driven
- Committed to quality



PHAR


Our focus, iron and carbohydrates applied
Pharmaceuticals
Carbohydrates
Animal Health
PHAR

Carbohydrates



- A world leader in cGMP carbohydrates for pharmaceutical use
- The only FDA and EMA inspected manufacturer of dextran APIs
- Unique polymer fractionation and derivatization platform
- Widest range of molecular weights – from 500 Da to >5,000,000Da
- GMP pilot and full-scale facilities for derivatives synthesis
- R&D programme focused on new applications and derivatives

PHAR

Examples of current applications for our carbohydrates

THERAPIES

- Nanoparticles for drug delivery and cell seperation
- Antibody-drug conjugates

EYEDROPS

- Lubrication
- Tear replacement
- Red eye relief

TISSUE AND ORGAN PRESERVATION

- Cornea transplants
- Wound care
- Synthesis of Hydrogels
- Lung storage and perfusion



CELL THERAPIES, CRYOPRESERVATION

- Cryopreservation media
- Thawing media
- Anti-clumping
- Nanoparticles for cell separation

VACCINES

- Adjuvants (e.g. DEAE Dextran)
- Carriers
- Stabilizing agents
- Lyophilisation

BLOC EXPA

- IV tre an
- Pre thr

PHAR

Pharmaceuticals



- IV iron carbohydrate compounds for treatment of iron deficiency with or without anae
- Three innovative brands – **Monofer®**, **Diafer®** and **CosmoFer®**
- Covering entire pharma value chain from R&D to marketing and sales
- Sales in >50 countries through affiliates and partners

PHAR

Pharmaceuticals

MonoFerric®
(ferric derisomaltose)
injection

Iron correction in ONE visit*

Diafer® | IV IRON FOR DIALYSIS

Tailor-made IV iron for patients on dialysis

CosmoFer®
IV, IM and TDI

Iron dextran administered in more than 82 million doses since 1993

* Up to 20 mg/kg[1]

Unique technology

ironMatrix



Components

The components of the ironMatrix consist of interchanging iron (III) and isomaltoside with low immunological activity



Delivery

The innovative matrix is based on the short linear structure of isomaltoside and iron



Release

Monofer is cha
strong iron binc
release of iron
little risk of labi

References
1. Kalra, P.A. et al. Port J Nephrol Hypert 2012; 26(1): 13-24
2. Jahn M.R. et al. European Journal of Pharmaceutics and Biopharmaceutics, Volume 78, Issue 3, August 2011, Pages 480-491
3. Monofer® SPC

P

Spearheading clinical research in ID & IDA

Clinical studies involving **>8,600 patients**

Ferwon NEPHRO | IDA | EXT — Head-to-head studies vs iron sucrose

Phosphare — Head-to-head studies vs ferric carboxymaltose

Ironman — First long-term* hard endpoin Randomized Controlled Trial in iron deficient heart failure p

* >1 year

Pharmacosmos Introduction

Pharmacosmos Therapeutics Inc

PHAR

Pharmacosmos Therapeutics Inc.

- Established September 2019 to commercialize Monoferric® (ferric derisomaltose) in the United States
- Wholly-owned affiliate of Pharmacosmos A/S located in Morristown, New Jersey
- Top-tier, focused commercial organization

2020
Monoferric
approved
in the US[7]

>148,000 doses administered
in the US[6]

Data accurate as of March 5, 2024

Fully integrated team of SARs, Ma
Access, MSLs and clinical educator

Extensive sales network establishe
hematologist oncologists, with cl
interfaces to **additional products**

Distribution setup through **buy-and**
across hospitals, community oncolo
and infusion clinics

Focused commercial organization,
current narrow portfolio, **ready to ta**
products and give them **full attent**

Omnichannel marketing capabilit
integrated with Veeva CRM

References:. **1.** Auerbach M et al. *Am J Hematol*. 2019;94(9):1007-1014. **2.** Bhandari S et al. *Nephrol Dial Transplant*. 2021;36:111-120. **3.** Wolf M et al. *JAMA*. 2020;323(5):432-443. **4.** Derman R et al. *Avm J Hematol*. 2017;92:286–291. **5.** Monoferric (ferric derisomaltose) Prescribing Information; Pharmacosmos Therapeutics, Inc., Morristown, NJ: 2022. **6.** Data on file. Pharmacosmos Therapeutics, Inc.

Forward-Looking Statements

This document contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, without limitation, statements regarding the business Pharmacosmos A/S ("Pharmacosmos") and of the proposed acqu Therapeutics, Inc. ("G1") by Pharmacosmos. The words "may," "will," "could," "would," "should," "expect," "plan," "anticipate "believe," "estimate," "predict," "project," "potential," "continue," "seek," "target" and similar expressions are intended to identi looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements document are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and imp that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements co document, including, without limitation: (i) risks and uncertainties relating to Pharmacosmos's financial performance and busines (ii) risks associated with the timing of the closing of the proposed transaction, including the risks that a condition to closing woul satisfied within the expected timeframe or at all or that the closing of the proposed transaction will not occur; (iii) uncertainties a of G1's stockholders will tender their shares in the offer; (iv) the possibility that a governmental entity may prohibit, delay or refu approval for the consummation of the transaction; (v) the possibility that competing offers will be made; (vi) the outcome of any proceedings that may be instituted against the parties and others related to the merger agreement; (vii) unanticipated difficulties o relating to the proposed transaction, the response of business partners and competitors to the announcement of the proposed trans potential difficulties in employee retention as a result of the announcement and pendency of the proposed transaction; (viii) G1's successfully demonstrate the efficacy and safety of its drug or drug candidates, and the preclinical or clinical results for its produ which may not support further development of such product candidates; (ix) comments, feedback and actions of regulatory agenc dependence on the commercial success of COSELA (trilaciclib); (xi) the inherent uncertainties associated with developing new p technologies and operating as commercial stage company; (xi) chemotherapy shortages; and (xiii) other risks identified in G1's S including G1's Annual Report on Form 10-K for the year ended December 31, 2023, and subsequent filings with the SEC. You a to place undue reliance on any forward-looking statements, which speak only as of the date they are made. Pharmacosmos and G obligation to publicly update or revise any such statements to reflect any change in expectations or in events, conditions or circu which any such statements may be based, or that may affect the likelihood that actual results will differ from those set forth in th looking statements.

Additional Information and Where to Find It

The tender offer referred to in this document has not yet commenced. This document is for informational purposes only an offer to purchase nor a solicitation of an offer to sell shares, nor is it a substitute for the tender offer materials that Pha and its acquisition subsidiary will file with the SEC upon commencement of the tender offer. At the time the tender offer commenced, Pharmacosmos and its acquisition subsidiary will cause to be filed a tender offer statement on Schedule TO and G1 will file a solicitation/recommendation statement on Schedule 14D-9 with respect to the tender offer. THE TENDER STATEMENT (INCLUDING AN OFFER TO PURCHASE, A RELATED LETTER OF TRANSMITTAL AND OTHER DOCUMENTS) AND THE SOLICITATION/RECOMMENDATION STATEMENT WILL CONTAIN IMPORTANT INFORMATION THAT SHOULD BE READ CAREFULLY AND CONSIDERED BY G1'S STOCKHOLDERS BEFORE ANY DECISION WITH RESPECT TO THE TENDER OFFER. Both the tender offer statement and the solicitation/recommendation statement will be mailed to G1's stockholders free of charge. A free copy of the tender offer statement and the solicitation/recommendation will also be made available to all stockholders of G1 by accessing https://investor.g1therapeutics.com/ or by contacting G1 Relations at ir@g1therapeutics.com. In addition, the tender offer statement and the solicitation/recommendation statement other documents filed with the SEC) will be available at no charge on the SEC's website: www.sec.gov, upon filing with

G1'S STOCKHOLDERS ARE ADVISED TO READ THE SCHEDULE TO AND THE SCHEDULE 14D-9, AS EACH AMENDED OR SUPPLEMENTED FROM TIME TO TIME, AND ANY OTHER RELEVANT DOCUMENTS FILED SEC WHEN THEY BECOME AVAILABLE BEFORE THEY MAKE ANY DECISION WITH RESPECT TO THE TEN BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT THE PROPOSED TRANSACTION AND PARTIES THERETO.

Exhibit 99.2

FAQ For G1 Therapeutics Employees

- Why did Pharmacosmos acquire the company?
    - We recognize the important benefits that Cosela brings to patients, and we believe that the expanded field presence realized through this acquisition will ensure that the product is available to more patients.
- Why do we think we can leverage this opportunity?
    - G1 and Pharmacosmos Therapeutics are calling on the same prescribers. The expertise and competencies required to commercialize Cosela and Monoferric are very similar. This transaction will allow broader reach for both products and will ensure more patients are treated.
- How are we going to invest in this opportunity?
    - Pharmacosmos is a growing organization. The company has a track record of consistent investment in growth opportunities as demonstrated by the establishment of affiliates in both the United States and China in recent years. It is our intention to continue to invest for long-term growth.
- How is this going to affect those working in the company, and what are the potential opportunities for employees joining PTI?
    - This has been a fast-moving transaction, and we are just beginning the planning for integration following the closing. So, it is too early to provide any specifics, but our goal is to work quickly to provide answers and clarity as soon as possible.
- Who will drive the integration?
    - We anticipate that the planning for integration and the post-closing integration will be a highly collaborative process with active participation from both sides.
- What are the key milestones for integration?
    - It is too early to provide specific milestones, as the planning is just beginning. We will provide updates as appropriate as the project moves forward.
- What are the plans for the RTP office?
    - At this early stage in the process, we have not yet made any decisions regarding the RTP office following closing.
- When can we expect to have clarity about future employment?

  This has been a fast-moving transaction, and we are just beginning the planning for integration following the closing. So, it is too early to provide any specifics, but our goal is to work quickly to provide answers and clarity as soon as possible.

- What are the company's plans for future growth?
    - We are still early in our growth journey, particularly in the US. This is a transformative transaction for our company and creates an outstanding platform for both organic and in-organic growth.
- What is the plan regarding which clinical programs to continue?
    - We will be assessing the options in the coming period, subject to close and cannot say at this stage
- What is the plan for expanding into new geographies?
    - We will be assessing the options in the coming period, subject to closing and cannot say at this stage
- What's the relation between iron deficiency and oncology? Do you know this space?
    - Hematologist oncologists treat both iron deficiency and oncology supportive care drugs such as Trilaciclib
- What do you see as the biggest challenge in driving this combined organization?
    - It is critical to patients and the great work that G1 has done that we all execute successfully on the closing of the transaction and the integration
- What attracted you the most about Cosela and G1?
    - We believe Cosela is a first in class drug, making a significant difference to patients
    - We believe G1 is complementary to our own business and strategy
- How would you describe the culture at Pharmacosmos?
    - We are a family-owned business where people are at the forefront and there is a long-term view
    - Our management structure results in quick decision-making and little hierarchy

Forward-Looking Statements

This document contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, statements regarding the business Pharmacosmos A/S ("Pharmacosmos") and of the proposed acquisition of G1 Therapeutics, Inc. ("G1") by Pharmacosmos. The words "may," "will," "could," "would," "should," "expect," "plan," "anticipate," "intend," "believe," "estimate," "predict," "project," "potential," "continue," "seek," "target" and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this document are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this document, including, without limitation: (i) risks and uncertainties relating to Pharmacosmos's financial performance and business operations; (ii) risks associated with the timing of the closing of the proposed transaction, including the risks that a condition to closing would not be satisfied within the expected timeframe or at all or that the closing of the proposed transaction will not occur; (iii) uncertainties as to how many of G1's stockholders will tender their shares in the offer; (iv) the possibility that a governmental entity may prohibit, delay or refuse to grant approval for the consummation of the transaction; (v) the possibility that competing offers will be made; (vi) the outcome of any legal proceedings that may be instituted against the parties and others related to the merger agreement; (vii) unanticipated difficulties or expenditures relating to the proposed transaction, the response of business partners and competitors to the announcement of the proposed transaction, and/or potential difficulties in employee retention as a result of the announcement and pendency of the proposed transaction; (viii) G1's ability to successfully demonstrate the efficacy and safety of its drug or drug candidates, and the preclinical or clinical results for its product candidates, which may not support further development of such product candidates; (ix) comments, feedback and actions of regulatory agencies; (x) G1's dependence on the commercial success of COSELA (trilaciclib); (xi) the inherent uncertainties associated with developing new products or technologies and operating as commercial stage company; (xi) chemotherapy shortages; and (xiii) other risks identified in G1's SEC filings, including G1's Annual Report on Form 10-K for the year ended December 31, 2023, and subsequent filings with the SEC. You are cautioned not to place undue reliance on any forward-looking statements, which speak only as of the date they are made. Pharmacosmos and G1 disclaim any obligation to publicly update or revise any such statements to reflect any change in expectations or in events, conditions or circumstances on which any such statements may be based, or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements.

Additional Information and Where to Find It

The tender offer referred to in this document has not yet commenced. This document is for informational purposes only and is neither an offer to purchase nor a solicitation of an offer to sell shares, nor is it a substitute for the tender offer materials that Pharmacosmos and its acquisition subsidiary will file with the SEC upon commencement of the tender offer. At the time the tender offer is commenced, Pharmacosmos and its acquisition subsidiary will cause to be filed a tender offer statement on Schedule TO with the SEC, and G1 will file a solicitation/recommendation statement on Schedule 14D-9 with respect to the tender offer. THE TENDER OFFER STATEMENT (INCLUDING AN OFFER TO PURCHASE, A RELATED LETTER OF TRANSMITTAL AND OTHER OFFER DOCUMENTS) AND THE SOLICITATION/RECOMMENDATION STATEMENT WILL CONTAIN IMPORTANT INFORMATION THAT SHOULD BE READ CAREFULLY AND CONSIDERED BY G1'S STOCKHOLDERS BEFORE ANY DECISION IS MADE WITH RESPECT TO THE TENDER OFFER. Both the tender offer statement and the solicitation/recommendation statement will be mailed to G1's stockholders free of charge. A free copy of the tender offer statement and the solicitation/recommendation statement will also be made available to all stockholders of G1 by accessing https://investor.g1therapeutics.com/ or by contacting Investor Relations at ir@g1therapeutics.com. In addition, the tender offer statement and the solicitation/recommendation statement (and all other documents filed with the SEC) will be available at no charge on the SEC's website: www.sec.gov, upon filing with the SEC.

G1'S STOCKHOLDERS ARE ADVISED TO READ THE SCHEDULE TO AND THE SCHEDULE 14D-9, AS EACH MAY BE AMENDED OR SUPPLEMENTED FROM TIME TO TIME, AND ANY OTHER RELEVANT DOCUMENTS FILED WITH THE SEC WHEN THEY BECOME AVAILABLE BEFORE THEY MAKE ANY DECISION WITH RESPECT TO THE TENDER OFFER, BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT THE PROPOSED TRANSACTION AND THE PARTIES THERETO.